血浆置换对特发性炎性肌病合并进展性间质性肺病患者的1年生存获益:系统综述与Meta分析
本系统综述与Meta分析纳入6项队列研究共148例抗MDA5阳性皮肌炎或抗合成酶综合征相关皮肌炎合并快速进展性间质性肺病且对标准治疗难治的患者,比较血浆置换(PLEX)联合其他治疗与未使用PLEX的1年生存率。PLEX组1年生存率较高(RR 1.59,95%CI 0.96-2.65,I²=52%),排除一项离群值后敏感性分析达统计学显著(RR 1.71,95%CI 1.30-2.25,I²=0%)。
要点
- 在148例难治性快速进展性间质性肺病的特发性炎性肌病患者中,PLEX组1年生存率RR 1.59(95%CI 0.96-2.65,I²=52%)。
- 排除一项离群值后敏感性分析RR 1.71(95%CI 1.30-2.25,I²=0%),达统计学显著。
- PLEX可能改善肺功能、影像学结局及KL-6和铁蛋白等关键血清生物标志物,但仅为趋势性提示。
核心结论
- 作为辅助治疗,PLEX改善了对标准治疗无应答的特发性炎性肌病合并快速进展性间质性肺病患者的1年生存率。
研究设计与样本
- 系统综述与Meta分析,检索Medline和EMBASE自建库至2023年8月,纳入随机对照试验、队列研究和病例对照研究。
- 最终纳入6项队列研究,共148例抗MDA5阳性皮肌炎或抗合成酶综合征相关皮肌炎合并快速进展性间质性肺病且对标准治疗(包括糖皮质激素、免疫抑制剂或静脉注射免疫球蛋白)难治的患者。
- 主要结局为1年生存率,统计分析使用RevMan 4.12.0版本。
主要发现
- 在148例患者中,PLEX联合其他治疗组较非PLEX组1年生存率更高(RR 1.59,95%CI 0.96-2.65,I²=52%)。
- 排除一项离群值后的敏感性分析达统计学显著(RR 1.71,95%CI 1.30-2.25,I²=0%)。
- 有趋势提示PLEX改善肺功能、影像学结局及KL-6和铁蛋白等关键血清生物标志物。
- 漏斗图不对称提示因阴性试验未报告而存在发表偏倚,所有研究偏倚风险均低。
局限性
- 漏斗图不对称提示因阴性试验未报告而存在发表偏倚。
- PLEX组1年生存率RR 1.59的95%CI 0.96-2.65跨1,未达统计学显著。
- 肺功能、影像学结局及KL-6和铁蛋白等生物标志物的改善仅为趋势性提示。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aimed to systematically evaluate the efficacy of plasma exchange (PLEX) in patients with idiopathic inflammatory myositis (IIM) complicated by interstitial lung disease (ILD). METHOD: We conducted a comprehensive literature search in Medline and EMBASE from their inception to August 2023, focusing on randomized controlled trials, cohort studies, and case-control studies involving IIM patients with ILD treated with PLEX compared to those treated with standard therapies. The primary outcome was the one-year survival rate. All the statistical analyses were performed using RevMan version 4.12.0. RESULTS: Out of 438 retrieved studies, 16 were selected for full-text review. Six cohort studies involving 148 patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis or antisynthetase syndrome-related dermatomyositis with rapidly progressive ILD refractory to standard treatments (including glucocorticoids, immunosuppressive agents, or intravenous immunoglobulin) met the inclusion criteria. Patients receiving PLEX in addition to other therapies demonstrated a greater one-year survival rate (relative risk [RR] 1.59, 95 % CI 0.96-2.65, I2 52 %) than did patients in the non-PLEX group. Significance was reached in a sensitivity analysis after excluding one outlier (RR 1.71, 95 % confidence intervals [CI] 1.30-2.25; I2 0 %). Additionally, there was a trend suggesting that PLEX improved lung function, radiographic outcomes, and key serum biomarkers, such as Krebs von den Lungen-6 and ferritin. Funnel plot asymmetry suggested publication bias due to the lack of reporting of negative trials. All studies had a low risk of bias. CONCLUSIONS: As an adjunctive therapy, PLEX improved one-year survival in IIM patients with rapidly progressive ILD who were unresponsive to standard treatments.
引用
- Tangborwornweerakul B, Phutthinart N, Disayabutr S, et al. One-year survival benefit of plasma exchange in idiopathic inflammatory myositis patients with progressive interstitial lung disease-a systemic review and meta-analysis. Semin Arthritis Rheum. 2024. PMID: 39423699. doi:10.1016/j.semarthrit.2024.152564
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。